NCT04318301: HT-COVID19

Hypertension in Patients Hospitalized With COVID-19

Completed Last updated 29 April 2020

What this trial tests

trial in COVID-19 in 275 participants. Completed in 30 March 2020.

Timeline

21 March 2020

Primary endpoint
28 March 2020

30 March 2020

Quick facts

Lead sponsor	Zhenhua Zen
Status	Completed
Study type	OBSERVATIONAL
Enrollment	275
Start date	21 March 2020
Primary completion	28 March 2020
Estimated completion	30 March 2020
Sites	1 location across China

Conditions studied

• COVID-19 — all drugs for COVID-19 →
• Hypertension — all drugs for Hypertension →

Sponsor

Zhenhua Zen

Who can join

Adults 18 to 100, any sex, with COVID-19 or Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Some studies have shown that the main pathogenesis of patients with covid19 is related to ACE2 receptor. Lung is one of the main organs, and there are many ACE2 receptors in cardiovascular system. ACEI / ARB is the main target of antihypertensive drugs. Previous reports suggested that there were large number of patients with covid19 also suffered from hypertension, suggesting that patients with hypertension may be the susceptible to covid19. Therefore, we try to follow up the patients admitted to Hankou hospital to explore the impact of hypertension and hypertension treatment on the severity and prognosis of patients with covid19, so as to provide new methods for the treatment of patients with covid19 in the future.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities - Role of gut microbiota dysbiosis.
   Viana SD, Nunes S, Reis F. · · 2020 · cited 122× · PMID 32683039 · DOI 10.1016/j.arr.2020.101123
2. Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week.
   Brojakowska A, Narula J, Shimony R, Bander J. · · 2020 · cited 120× · PMID 32305401 · DOI 10.1016/j.jacc.2020.04.028
3. Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19.
   Pereira GJDS, Leão AHFF, Erustes AG, Morais IBM, et al · · 2021 · cited 36× · PMID 33920748 · DOI 10.3390/ijms22084067
4. Cardiovascular disease and COVID-19: les liaisons dangereuses.
   Barison A, Aimo A, Castiglione V, Arzilli C, et al · · 2020 · cited 21× · PMID 32391719 · DOI 10.1177/2047487320924501
5. Angiotensin-converting enzyme 2: a double-edged sword in COVID-19 patients with an increased risk of heart failure.
   Razeghian-Jahromi I, Zibaeenezhad MJ, Lu Z, Zahra E, et al · · 2021 · cited 19× · PMID 32844337 · DOI 10.1007/s10741-020-10016-2
6. Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin system blockers in SARS-CoV-2 infections.
   Speth RC. · · 2020 · cited 11× · PMID 32304146 · DOI 10.1002/ddr.21672
7. Understanding the role of nACE2 in neurogenic hypertension among COVID-19 patients.
   Kulkarni PG, Sakharkar A, Banerjee T. · · 2022 · cited 7× · PMID 34848886 · DOI 10.1038/s41440-021-00800-4
8. Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19.
   Hamouche W, Bisserier M, Brojakowska A, Eskandari A, et al · · 2021 · cited 6× · PMID 33373644 · DOI 10.1016/j.yjmcc.2020.12.009